<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1834">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05519137</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY-20-01772</org_study_id>
    <nct_id>NCT05519137</nct_id>
  </id_info>
  <brief_title>Using a Wireless Controller to Deliver a Lighting Intervention to Persons With Dementia</brief_title>
  <official_title>Using a Wireless Controller to Deliver a Lighting Intervention to Persons With Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the effect of a tailored lighting intervention controlled by the Readings At Desk&#xD;
      (RAD) controller on sleep and mood in Alzheimer's disease participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each participant will be enrolled for 22 weeks. Participants will be randomly assigned to&#xD;
      receive either the active or control lighting condition. Each lighting condition will be 8&#xD;
      weeks in length. After a 4 week washout, each participant will crossover to the opposite&#xD;
      condition. Assessments will be performed before and at the end of each lighting intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2022</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Participants will randomly be assigned to initially receive the active or control lighting intervention</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep disturbance using the Pittsburgh Sleep Quality Index</measure>
    <time_frame>up to 22 weeks</time_frame>
    <description>The Pittsburgh Sleep Quality Index (PSQI) is composed of 19 items that generate 7 component scores. The sum of the 7 component scores yields a single global score with a range of 0 to 21. A global score &gt;5 is considered to indicate sleep disturbances. A lower global score indicates improvement in sleep disturbance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depression screening utilizing the Cornell Scale for Depression in Dementia (CSDD)</measure>
    <time_frame>up to 22 weeks</time_frame>
    <description>The CSDD is a a 19-item tool designed to rate symptoms of depression in patients with dementia. This tool evaluates the presence and extent of mood-related signs. Scores range from 0 to 38 with a higher score indicating higher depressive symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep efficiency measured by actigraphy</measure>
    <time_frame>up to 22 weeks</time_frame>
    <description>Sleep efficiency is calculated from the wrist worn actigraph by the software program as the percentage of the time in bed spent sleeping. The ratio of total sleep time (TST) to total time in bed (TIB) multiplied by 100 to yield a percentage.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Active lighting intervention then Control lighting condition</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each lighting condition will be 8 weeks in length. After a 4 week washout, each participant will crossover to the opposite condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control lighting condition then Active light intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each lighting condition will be 8 weeks in length. After a 4 week washout, each participant will crossover to the opposite condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active lighting intervention</intervention_name>
    <description>Lighting intervention designed to impact the circadian system</description>
    <arm_group_label>Active lighting intervention then Control lighting condition</arm_group_label>
    <arm_group_label>Control lighting condition then Active light intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control lighting intervention</intervention_name>
    <description>Lighting intervention designed to have no impact on the circadian system</description>
    <arm_group_label>Active lighting intervention then Control lighting condition</arm_group_label>
    <arm_group_label>Control lighting condition then Active light intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Diagnosis of Alzheimer's disease with a Mini Mental Score Examination (MMSE) between 0&#xD;
             and 19&#xD;
&#xD;
          -  a score &gt;5 on the PSQI.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - use of sleep medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariana Figueiro, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai Icahn School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Plitnick, BSN</last_name>
    <phone>518-242-4603</phone>
    <email>barbara.plitnick@mountsinai.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Light and Health Research Center</name>
      <address>
        <city>Menands</city>
        <state>New York</state>
        <zip>12204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mariana Figueiro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2022</verification_date>
  <study_first_submitted>August 25, 2022</study_first_submitted>
  <study_first_submitted_qc>August 25, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2022</study_first_posted>
  <last_update_submitted>August 25, 2022</last_update_submitted>
  <last_update_submitted_qc>August 25, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Mariana Figueiro</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Since this data collection occurs in a population with Alzheimer's disease, participants are generally not interested in individual results.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

